论文部分内容阅读
目的评价不经筛选的孕妇健康足月新生儿乙肝疫苗肌肉、皮内联合注射新方案的免疫应答及经济效益。方法实验组:第1针乙肝疫苗30μg肌肉注射,第2、3针各2μg皮内注射;对照组:3针乙肝疫苗均采用肌肉注射,第1针30μg,第2、3针各为10μg。以0、6、12月时的HBsAg及抗-HBs观察免疫应答。结果2组于出生时血各有4例HBsAg阳性,于6及12月时2组HBsAg全部阴性。于6月时2组抗-HBs>10IU-1的阳性率分别为76.27%及83.08%,抗-HBs的效价分别为42.25及60.25IU-1;12月时抗-HBs>10IU-1的阳性率分别为83.72%及92.45%,抗-HBs的滴度分别为74.45及87.10IU-1。经χ2及t检验,2组间无显著性差异。结论新方案组的免疫效果与传统方案相似,但新方案组可节省1/3乙肝疫苗用量并可节省大量孕妇筛检的费用。
OBJECTIVE: To evaluate the immune response and economic benefits of a new program of intramuscular and intradermal injection of healthy pregnant newborn infants without screening. Methods Experimental group: the first injection of hepatitis B vaccine 30μg intramuscular injection, the second and third injection of 2μg intradermal injection; control group: 3-pin hepatitis B vaccine were injected intramuscularly, the first needle 30μg, the second and third needle 10μg each. Immune responses were observed with HBsAg and anti-HBs at 0, 6, and 12 months. Results In the two groups, there were 4 cases of HBsAg positive at the time of birth and 2 cases at the 6th and 12th month respectively. The positive rates of anti-HBs> 10IU-1 in two groups were 76.27% and 83.08% respectively at the month of June. The anti-HBs titers were 42.25 and 60.25IU-1, respectively. The positive rates of-HBs> 10IU-1 were 83.72% and 92.45% respectively, and the titers of anti-HBs were 74.45 and 87.10IU-1, respectively. By χ2 and t test, no significant difference between the two groups. Conclusion The immunization effect of the new plan group is similar to the traditional one, but the new plan group can save 1/3 hepatitis B vaccine and save a large number of pregnant women screening costs.